<DOC>
	<DOCNO>NCT01212250</DOCNO>
	<brief_summary>Patients cirrhosis age 18 75 year esophageal varix enrol . After baseline evaluation , participant randomize receive either Placebo Carvedilol 12.5 mg BD . After randomization follow one year .</brief_summary>
	<brief_title>Carvedilol Pre-primary Prophylaxis Esophageal Varices Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Esophageal Gastric Varices</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<criteria>Patients cirrhosis age 18 75 year esophageal gastric varix . Any contraindication betablockers Any past EVL sclerotherapy Any past history surgery portal hypertension Significant cardio pulmonary comorbidity Any malignancy Refusal participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>